S D Comer1, C L Hart, A S Ward, M Haney, R W Foltin, M W Fischman. 1. Division on Substance Abuse, New York State Psychiatric Institute and Department of Psychiatry, College of Physicians and Surgeons of Columbia University, 1051 Riverside Drive, Unit 120, New York, NY 10032, USA. sdc10@columbia.edu
Abstract
RATIONALE: Although methamphetamine use has increased over the past several years, few studies have evaluated the effects of repeated methamphetamine administration in humans. OBJECTIVES: Because methamphetamine is often taken in a pattern of repeated use followed by a period of abstinence, the present study sought to evaluate the effects of repeated methamphetamine administration in humans. The hypothesis was that tolerance would develop to methamphetamine's effects. METHODS:Seven normal, healthy volunteers participated in a 15-day residential study. Participants completed subjective-effects questionnaires and psychomotor performance tasks repeatedly throughout the experimental day. Oral methamphetamine (5, 10 mg BID) was administered on days 4-6 and 10-12; placebo was administered on all other study days. RESULTS: Relative to placebo baseline, only two "positive" subjective ratings ("I feel a good drug effect" and "I feel high") were significantly elevated, and only on the 1st day of methamphetamine administration. In contrast, numerous "negative" ratings, including "I feel..." "a bad drug effect," "dizzy," and "flu-like symptoms" were elevated on the 3rd day of methamphetamine administration. Total caloric intake decreased and sleep was disrupted after methamphetamine administration, relative to baseline. CONCLUSIONS: The pattern of methamphetamine's positive subjective effects were altered with chronic administration such that tolerance, or a decreased effect, occurred after repeated administration. In contrast, methamphetamine's negative subjective effects increased over days. These results suggest that in this population of normal volunteers, the abuse liability of oral methamphetamine is relatively low.
RCT Entities:
RATIONALE: Although methamphetamine use has increased over the past several years, few studies have evaluated the effects of repeated methamphetamine administration in humans. OBJECTIVES: Because methamphetamine is often taken in a pattern of repeated use followed by a period of abstinence, the present study sought to evaluate the effects of repeated methamphetamine administration in humans. The hypothesis was that tolerance would develop to methamphetamine's effects. METHODS: Seven normal, healthy volunteers participated in a 15-day residential study. Participants completed subjective-effects questionnaires and psychomotor performance tasks repeatedly throughout the experimental day. Oral methamphetamine (5, 10 mg BID) was administered on days 4-6 and 10-12; placebo was administered on all other study days. RESULTS: Relative to placebo baseline, only two "positive" subjective ratings ("I feel a good drug effect" and "I feel high") were significantly elevated, and only on the 1st day of methamphetamine administration. In contrast, numerous "negative" ratings, including "I feel..." "a bad drug effect," "dizzy," and "flu-like symptoms" were elevated on the 3rd day of methamphetamine administration. Total caloric intake decreased and sleep was disrupted after methamphetamine administration, relative to baseline. CONCLUSIONS: The pattern of methamphetamine's positive subjective effects were altered with chronic administration such that tolerance, or a decreased effect, occurred after repeated administration. In contrast, methamphetamine's negative subjective effects increased over days. These results suggest that in this population of normal volunteers, the abuse liability of oral methamphetamine is relatively low.
Authors: J Cobb Scott; Steven Paul Woods; Georg E Matt; Rachel A Meyer; Robert K Heaton; J Hampton Atkinson; Igor Grant Journal: Neuropsychol Rev Date: 2007-09 Impact factor: 7.444
Authors: Matthew G Kirkpatrick; Erik W Gunderson; Frances R Levin; Richard W Foltin; Carl L Hart Journal: Psychopharmacology (Berl) Date: 2011-07-12 Impact factor: 4.530
Authors: Carl L Hart; Amie S Ward; Margaret Haney; Jennifer Nasser; Richard W Foltin Journal: Psychopharmacology (Berl) Date: 2003-05-07 Impact factor: 4.530
Authors: M Farré; R de la Torre; B O Mathúna; P N Roset; A M Peiró; M Torrens; J Ortuño; M Pujadas; J Camí Journal: Psychopharmacology (Berl) Date: 2004-04-08 Impact factor: 4.530
Authors: Tânia Capelôa; Francisco Caramelo; Carlos Fontes-Ribeiro; Célia Gomes; Ana P Silva Journal: Neurotox Res Date: 2014-03-21 Impact factor: 3.911
Authors: Marc E Mooney; David V Herin; Joy M Schmitz; Nidal Moukaddam; Charles E Green; John Grabowski Journal: Drug Alcohol Depend Date: 2008-12-05 Impact factor: 4.492
Authors: Matthew G Kirkpatrick; Margaret Haney; Suzanne K Vosburg; Sandra D Comer; Richard W Foltin; Carl L Hart Journal: Psychopharmacology (Berl) Date: 2008-12-04 Impact factor: 4.530
Authors: Marco Bortolato; Roberto Frau; A Paola Piras; William Luesu; Valentina Bini; Giacomo Diaz; Gianluigi Gessa; M Grazia Ennas; M Paola Castelli Journal: Neurotox Res Date: 2009-02-25 Impact factor: 3.911
Authors: Carl L Hart; Erik W Gunderson; Audrey Perez; Matthew G Kirkpatrick; Andrew Thurmond; Sandra D Comer; Richard W Foltin Journal: Neuropsychopharmacology Date: 2007-09-12 Impact factor: 7.853